A new targeted treatment for a rare and aggressive bile duct cancer has been approved by NICE, offering patients longer ...
Also known as Ziihera, the antibody treatment targets a protein called HER2, which stimulates tumour growth. It works by ...
ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary ...
Jazz Pharma's Ziihera and Eli Lilly's Jaypirca, respectively – have been recommended by reimbursement agency NICE for NHS use ...
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...
New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (CYCC) (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing ...
The safety and short-term efficacy of selective internal radiation therapy combined with systemic treatment for unresectable malignant hepatic tumors in Chinese patients. This is an ASCO Meeting ...
Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...
The GAP regimen did not improve overall survival compared to GC in advanced BTCs, with similar median OS between groups. GAP treatment resulted in higher rates of severe hematologic and nonhematologic ...
Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results